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The American Society for Clinical Oncology (ASCO) held
its 40th annual meeting in New Orleans, LA, USA on 5–8
June 2004. There were more than 20 oral presentations
and greater than 150 poster presentations devoted to
breast cancer research. Each of these presentations
contributes to advances in the science of breast cancer
prevention, diagnosis, prognosis and treatment.
Diagnosis
Emerging diagnostic tools in breast cancer include
magnetic resonance imaging (MRI) and positron emission
tomography evaluation. Data presented this year add to
the growing understanding of how these modalities can
be applied to patient management.
The use of MRI in evaluation of the breast remains a
controversial topic. In an abstract presented by Dr Schnall
on behalf of the International Breast MRI Consortium, the
value of MRI in multifocal disease was assessed [1]. This
multicenter prospective trial enrolled 1004 women with
suspicious mammograms and/or clinical findings. Prior to
undergoing biopsy, these women received mammograms
and underwent MRI of the breast. Biopsy of the index
lesion was malignant in 428 women. Of these, 103
women had a second area of suspicion indicated by MRI
compared with 36 women by mammogram alone. Biopsy
confirmed multifocal disease in 56 of 78 MRI-detected
abnormalities and in 17 of 20 mammogram-detected
abnormalities. This study confirms the higher yield of MRI
for detecting multifocal disease than the mammogram. It
has yet to be shown that this higher yield will translate into
clinical benefit for patients. Randomized trials to assess
this benefit are warranted.
Surgical treatment
One of the biggest concerns expressed by breast cancer
patients prior to surgical intervention is the effect of axillary
evaluation on mobility, pain symptoms and risk of
lymphedema. Studies presented this year address the
optimal approach to axillary evaluation in terms of
morbidity, and address whether certain subgroups of
women do not require an axillary evaluation.
Two randomized trials were presented that address the
role of axillary evaluation in clinically node-negative breast
cancer patients. The initial results of the ALMANAC study
were presented by Dr Mansel [2]. This study compared
sentinel lymph node biopsy with axillary dissection, with
regards to primary outcomes of arm and axillary morbidity,
the quality of life and costs in terms of resources. A total
of 1031 patients were randomized to sentinel biopsy or to
axillary dissection. If the sentinel biopsy was positive,
patients went on to full axillary evaluation. Results of this
trial confirmed the decreased morbidity of sentinel node
biopsy in comparison with axillary dissection, with
decreased risk of sensory loss and lymphedema (relative
risk, 0.39 and 0.28, respectively), with decreased hospital
stays, drain usage and operative time (P < 0.001), and
with improved quality of life and self-rated arm morbidity at
3 months (P < 0.01).
Dr Holmberg reported the results of the International
Breast Cancer Study Group Trial 10-93, which
randomized women aged 60 years or older to surgery with
or without axillary dissection [3]. Both groups received
adjuvant tamoxifen following surgery. In this study of 473
women, with 6 years of median follow-up, the 5-year
disease-free survival in the surgery plus axillary clearance
group versus the surgery alone group was 71% versus
70% (P = 0.46). The study’s respective 5-year overall
survival (OS) was 78% versus 80% (P = 0.61). The
quality of life was significantly better in the no axillary
surgery group. In the group assigned to axillary clearance
27% were node-positive, suggesting that the study is
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underpowered to detect a modest difference in disease-
free survival or OS. In the setting of an effective alternative
to axillary clearance such as sentinel node biopsy that
results in less morbidity, lymph node assessment of some
form should still be considered the standard of care.
Systemic therapy
Several studies presented this year evaluated neoadjuvant
regimens. In the following, two studies — one addressing
the use of trastuzumab in Her2/neu-positive patients and
the other comparing hormonal therapy with chemotherapy —
are reviewed.
In a randomized study conducted at the MD Anderson
Cancer Center and presented by Dr Buzdar, the addition
of trastuzumab in Her2/neu-positive patients to pre-
operative chemotherapy was evaluated [4]. Patients were
randomized to four cycles of paclitaxel followed by four
cycles of 5-fluorouracil, epirubicin and cyclophosphamide
with or without trastuzumab weekly at 2 mg/kg for
24 weeks. The study was planned for 164 patients, but
was stopped by an independent Data Monitoring
Committee after 34 patients enrolled. The pathologic
complete response rate was 67% in the chemotherapy
plus trastuzumab arm and was 25% in the chemotherapy
alone arm (P = 0.02). There were no cardiac events in
either arm. The study will continue to accrue patients to
the trastuzumab arm, which will provide additional safety
data. Due to the early closure of the control arm, however,
the study will not provide survival data. The use of
trastuzumab in the neoadjuvant setting outside of a clinical
trial cannot be justified on the basis of this small number
of patients alone as safety data are still pending.
A study addressing the use of neoadjuvant hormonal therapy
was presented by Dr Semiglazov [5]. Postmenopausal
women (121 patients) with estrogen receptor-positive
tumors were randomized to doxorubicin + paclitaxel chemo-
therapy (every 3 weeks) or to hormonal therapy with
anastrazole. Clinical and mammographic response rates
were not significantly different and there was a trend towards
increased breast-conserving surgery in the hormonal arm
that did not reach statistical significance (37.9% versus
20.6%, P= 0.054). The authors conclude that neoadjuvant
hormonal therapy is a reasonable alternative to chemo-
therapy, especially when low toxicity is desired. This study,
while of a small size, supports the ongoing evaluation of
hormonal therapy in the neoadjuvant setting.
Prognosis
A variety of emerging technologies have the possibility of
providing tools to aid in decision management of early
breast cancer.
The online model ADJUVANT! is designed to predict OS,
breast cancer-specific survival and event-free survival in
breast cancer patients based upon standard prognostic
features of the tumor and the patient with or without
systemic therapy. At the ASCO 2004 meeting, Dr Olivotto
presented a study designed to validate this model [6].
Utilizing 4083 patients with early stage breast cancer
captured by the British Columbia Cancer Agency, actual
survival information was compared with predicted survival
based upon the ADJUVANT! model. The 10-year
predicted survival and observed survival were reliable in
the population as a whole, within 1%. It is noted that this
model was overly optimistic for the combined effects of
chemotherapy plus tamoxifen and that lymphovascular
invasion is a factor that should be added to future models.
Information regarding the use of gene expression profiling
to identify chemotherapy resistance, to predict response
and to predict clinical benefit continues to grow. This use
of this technology was evaluated in the neoadjuvant
setting. Four abstracts were presented this year in an
integrated education session.
Dr Yoshimoto presented data on a group of patients
receiving neoadjuvant therapy with paclitaxel [7].
Grouping these patients based upon clinical and
pathologic response, gene expression profiling using
cDNA microarrays (Agilent Oligo Array Palo Alto, CA,
USA) reliably predicted sensitive and resistant disease.
Using a seven-gene prediction set, the estimated
prediction error was 3% (1/34). In an interesting aside,
two genes were identified (CYP2c8 and BUB1b) that
predicted granulocytopenia.
In the second abstract of this session, Dr Gianni presented
a study utilizing RT-PCR (Genomic Health, Redwood City,
CA, USA) to identify gene clusters to predict response to
neoadjuvant therapy (paclitaxel and doxorubicin) [8]. From
a group of 384 candidate genes, 87 were identified that
correlated gene expression with pathologic complete
response. Thirty of these genes clustered in three groups:
an estrogen receptor group, a proliferation group and an
immune group. Multivariate analysis confirmed that the use
of gene clusters in this study was more predictive of
chemotherapy response than single genes.
In counterpoint to this, Dr Hannemann presented a study
using neoadjuvant doxorubicin with cyclophosphamide or
docetaxel (49 patients) in which no discernable predictor
of response was identified using cDNA microarrays (NKI
microarray, Amsterdam, The Netherlands) [9]. While a
predictive gene set could not be identified, a change in
expression of a group of 30 genes could reliably (91%
accuracy) distinguish pre and post specimens among
responders.
In a study presented by Dr Pusztai, predictors of response
were identified on two different cDNA array profiling277
platforms (Affymetrix GeneChip, Santa Clara, CA, USA;
and Millennium, Kingston, Ontario, Canada) with only 17
genes overlapping [10]. When the predictive genes of one
platform were utilized on the opposing platform, however,
much lower accuracy was obtained. In discussion during
this integrated session, Dr Simon specifically highlighted
the need for large, prospective trials with independent
validation and bioinformatics coordination. The future use
of gene profiling remains to be clarified and cannot be
considered ready for use in clinical practice at this time.
Metastatic disease
Two abstracts presented evaluated the role of gene
polymorphisms in aromatase encoding genes. Dr Lloveras
and colleagues evaluated the efficacy of letrozole in
metastatic breast cancer patients in relation to single
nucleotide polymorphisms (SNPs) [11]. CYP19 encodes
a human steroid aromatase enzyme; the 3′ untranslated
region (UTR) and an intronic region were examined for
SNPs. In 65 patients, 46% had SNP variations in the UTR
region. The time to progression (TTP) on letrozole of the
SNP variation of the CYP19 UTR versus the wild-type
CYP19 UTR was 525 days versus 196 days (P = 0.02).
The authors conclude that the presence of SNPs on the 3′
UTR of CYP19 is associated with improved TTP and may
help in selecting patients for letrozole intervention. These
data from a prospective cohort study give insight on the
variability of response seen in patients with estrogen
receptor-positive tumors to letrozole. However, patients
without SNPs in the 3′ UTR should not be excluded from
the use of letrozole based on current data.
In a study presented by Dr Stearns, genotypic variations of
CYP 2D6 (CYP 2D6*4 and CYP 2D6*6), which encodes
a cytochrome P450 metabolic enzyme, as well as the use
of CYP2D6 inhibitors (specifically sertraline and paroxetine,
but not venlafaxine) reduced serum concentrations of
endoxifen, an active metabolite of tamoxifen [12]. They
caution that until the clinical implications of these findings
are understood, prescribing practices should not change.
The use of novel approaches for assessment of tumor
activity beyond radiographic evaluation represents an
arena of growth and promise. These technologies may one
day change the method by which response to treatment is
measured.
The utilization of circulating tumor cell (CTC) levels as a
predictor in metastatic breast cancer of progression-free
survival and of OS was presented by Dr Hayes. This group
reported on 177 patients who underwent CTC
measurements prior to instituting a new systemic therapy
as well as 3–4 weeks after beginning this therapy [13].
Patients with ≥5 CTCs/7.5 ml at baseline had a
significantly shorter progression-free survival (2.7 months
versus 7.0 months, P = 0.0001) and OS (10.1 months
versus >18 months, P = 0.0001) compared with patients
with <5 CTCs/7.5 ml. At follow-up sampling after
3–4 weeks of therapy, patients with a CTC level ≥5 at
baseline whose CTCs were reduced to <5 had equivalent
progression-free survival and OS to patients who began
treatment with <5 CTCs. In multivariate analysis, CTC
levels were the strongest predictor of poor outcome. This
method of assessing response and prognostication may
represent an important addition to current disease
assessment tools. The authors speculate that patients
without a significant decrease in CTCs after 3–4 weeks of
therapy may benefit from an alternative systemic therapy.
Randomized trials will be required to test this hypothesis.
This year, in the area of metastatic breast cancer manage-
ment, two chemotherapeutic abstracts were presented.
The first of these abstracts addressed the optimal dosing
schedule of paclitaxel, while the other evaluated the
potential advantage of doublet chemotherapy versus
single-agent chemotherapy.
As a late-breaking abstract, CALGB 9840, which
evaluated the efficacy of weekly versus 3-weekly paclitaxel
in metastatic breast cancer, was presented by Dr
Seidman [14]. A total of 738 patients were randomized to
the two treatment arms. This study was also designed to
evaluate the efficacy of trastuzumab for patients with
tumors without Her2/neu overexpression. Patients
received paclitaxel as either first-line or second-line
therapy for metastatic breast cancer and had previously
received anthracycline-based therapy. Weekly paclitaxel
compared with the every 3-week regimen resulted in an
improved response rate (40% versus 29%, P = 0.017)
and an improved TTP (9 months versus 5 months,
P = 0.0008), and a trend toward improved survival
(24 months versus 16 months, P = 0.17). The addition of
trastuzumab in Her2/neu ‘normal’ patients did not
enhance the efficacy of paclitaxel therapy. In terms of
toxicity, weekly paclitaxel caused more grade III/IV sensory
and motor neuropathy, but caused less granulocytopenia.
A planned novel trial design allowed the use of patients
from CALGB 9342 in the paclitaxel every 3 weeks study
arm, which has raised some controversy.
On 19 May 2004, the Food and Drug Administration
approved gemcitabine in combination with paclitaxel as
first-line therapy for metastatic breast cancer in patients
previously undergoing anthracycline-based therapy in the
adjuvant setting, based upon data from the JHQG trial
presented at the 2003 San Antonio Breast Cancer
Symposium by Dr O’Shaughnessy. An interim analysis of
the JHQG trial was presented by Dr Albain [15]. In this
study of 529 women, patients were randomized to
gemcitabine + paclitaxel versus paclitaxel alone. At a
preplanned interim analysis, gemcitabine + paclitaxel
resulted in improved TTP (5.2 months versus 2.9 months,
Available online http://breast-cancer-research.com/content/6/6/275278
P < 0.0001) and an improved median OS (18.5 months
versus 15.8 months, P = 0.018). Gemcitabine + paclitaxel
and paclitaxel alone were well tolerated, with few omitted
or reduced doses. Gemcitabine + paclitaxel resulted in an
increased incidence of grade III/IV neutropenia (48%
versus 11%). Only 14% of patients in the paclitaxel arm
went on to gemcitabine therapy after progression.
Definitive conclusions are pending as the interim
prespecified significance value for OS of P < 0.0001 was
not met.
The aforementioned abstracts represent only a small
fraction of the efforts over the past year presented at
ASCO’s annual meeting. Contributing research continues
to expand all areas of breast cancer science. Advances in
understanding of diagnostic tools and therapeutic
approaches continue. The role of genomics remains to be
clarified but suggests that a future of carefully guided
therapies designed for the most benefit and the least
amount of risk may be possible. Above all, this year’s
ASCO meeting showcased the expanding understanding
of breast cancer biology. As always, our eagerness to
advance this field must be tempered with rational trial
design, with statistically appropriate analyses with
independent validation as required and always with an eye
towards the allocation of patient resources and safety.
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